Malaria Pathogenesis Laboratory



  • Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes. Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00355-17. doi: 10.1128/AAC.00355-17. Print 2017 Aug.
  • Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections. PLoS One. 2017 May 12;12(5):e0177445. doi: 10.1371/journal.pone.0177445. eCollection 2017.
  • VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping data in Plasmodium vivax populations. PLoS Negl Trop Dis. 2017 Mar 31;11(3):e0005465. doi: 10.1371/journal.pntd.0005465. eCollection 2017 Mar.
  • Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility. Antimicrob Agents Chemother. 2015 Nov 2;60(1):361-7. doi: 10.1128/AAC.02207-15.
  • Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry. Malar J. 2015 Oct 24;14(1):417. doi: 10.1186/s12936-015-0940-8.
  • Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax. Antimicrob Agents Chemother. 2015 Oct;59(10):6117-24. doi: 10.1128/AAC.00874-15. Epub 2015 Jul 20.
  • Contrasting ex vivo efficacies of "reversed chloroquine" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. Antimicrob Agents Chemother. 2015 Sep;59(9):5721-6. doi: 10.1128/AAC.01048-15. Epub 2015 Jul 6.
  • A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015 Jun 18;522(7556):315-20. doi: 10.1038/nature14451.
  • Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nat Commun. 2014 Nov 25;5:5521. doi: 10.1038/ncomms6521.
  • Genetic diversity and population structure of Plasmodium vivax in Central China. Malar J. 2014 Jul 9;13:262. doi: 10.1186/1475-2875-13-262.
  • KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother. 2014 Sep;58(9):5060-7. doi: 10.1128/AAC.02727-13. Epub 2014 Jun 9.
  • Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med. 2013 Mar 20;5(177):177ra37. doi: 10.1126/scitranslmed.3005029.
  • Effective preparation of Plasmodium vivax field isolates for high-throughput whole genome sequencing. PLoS One. 2013;8(1):e53160. doi: 10.1371/journal.pone.0053160. Epub 2013 Jan 4.